3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
23
Carcinoma, Transitional Cell
15
Neoplasms
14
Ovarian Neoplasms
13
Carcinoma, Renal Cell
13
Urinary Bladder Neoplasms
12
Carcinoma, Merkel Cell
12
Squamous Cell Carcinoma of Head and Neck
11
Colorectal Neoplasms
8
Triple Negative Breast Neoplasms
7
Pancreatic Neoplasms
7
Neoplasm Metastasis
7
Melanoma
7
Stomach Neoplasms
6
Recurrence
5
Breast Neoplasms
5
Carcinoma, Hepatocellular
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Lymphoma, Non-Hodgkin
2
Kidney Neoplasms
2
Kidney Diseases
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Central Nervous System Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Ovarian Epithelial
2
Uveal Melanoma
1
Urothelial Cancer
1
Interventions
Gemcitabine
7
Cisplatin
5
pembrolizumab
4
enfortumab vedotin
4
Mitomycin
4
Trastuzumab
3
Pemetrexed
3
Carboplatin
3
dodecyl maltoside
2
atezolizumab
2
Sunitinib
2
vinflunine
1
valrubicin
1
tucatinib
1
palbociclib
1
niraparib
1
motexafin gadolinium
1
cabozantinib
1
avelumab
1
apatorsen
1
Water
1
VMBP protocol
1
Standard of Care
1
Radiation Dose Hypofractionation
1
Nivolumab
1
Neoadjuvant Therapy
1
Immunoglobulins, Intravenous
1
Gels
1
GSK-3326595
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urologic Neoplasms
×
avelumab
×
Clear all
NCT02603432
2024-03-27
JAVELIN Bladder 100
Pfizer
Phase 3
Completed
700 enrolled
35 charts
1 FDA